Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 2004 Jan;161(1):169-71.

Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients.

Author information

  • 1Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA. zaratec@intra.nimh.nih.gov

Abstract

OBJECTIVE:

The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode.

METHOD:

Immediately following remission of a manic episode treated with the combination of a typical antipsychotic (perphenazine) and a mood stabilizer (lithium, carbamazepine, or valproate), 37 patients were randomly assigned to 6 months of double-blind treatment in which in addition to the mood stabilizer they received either continued perphenazine treatment or placebo.

RESULTS:

Patients randomly assigned to continue perphenazine treatment, relative to those who discontinued it, were more likely to have a shorter time to depressive relapse, discontinue the study, and have increased rates of dysphoria, depressive symptoms, and extrapyramidal symptoms.

CONCLUSIONS:

There were no short-term benefits with the continued use of a typical antipsychotic after achieving remission from an episode of acute mania. In fact, its continued use was associated with detrimental effects.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk